Literature DB >> 18565828

Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease.

N Brouwers1, K Sleegers, S Engelborghs, S Maurer-Stroh, I Gijselinck, J van der Zee, B A Pickut, M Van den Broeck, M Mattheijssens, K Peeters, J Schymkowitz, F Rousseau, J-J Martin, M Cruts, P P De Deyn, C Van Broeckhoven.   

Abstract

OBJECTIVE: Loss-of-function mutations in the progranulin gene (PGRN) were identified in frontotemporal lobar degeneration (FTLD) with ubiquitin-immunoreactive neuronal inclusions (FTLD-U). We assessed whether PGRN also contributes to genetic risk for Alzheimer disease (AD) in an extended Belgian AD patient group (n = 779, onset age 74.7 +/- 8.7 years).
METHODS: A mutation analysis of the PGRN coding region was performed. The effect of missense mutations was assessed using in silico predictions and protein modeling. Risk effects of common genetic variants were estimated by logistic regression analysis and gene-based haplotype association analysis.
RESULTS: We observed seven missense mutations in eight patients (1.3%). Convincing pathogenic evidence was obtained for two missense mutations, p.Cys139Arg and p.Pro451Leu, affecting PGRN protein folding and leading to loss of PGRN by degradation of the misfolded protein. In addition, we showed that PGRN haplotypes were associated with increased risk for AD.
CONCLUSIONS: Our data support a role for PGRN in patients with clinically diagnosed Alzheimer disease (AD). Further, we hypothesize that at least some PGRN missense mutations might lead to loss of functional protein. Whether the underlying pathology in our cases proves to be AD, frontotemporal lobar degeneration, or a combination of the two must await further investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565828     DOI: 10.1212/01.wnl.0000319688.89790.7a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  68 in total

Review 1.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

2.  rs5848 polymorphism and serum progranulin level.

Authors:  Ging-Yuek R Hsiung; Alice Fok; Howard H Feldman; Rosa Rademakers; Ian R A Mackenzie
Journal:  J Neurol Sci       Date:  2010-11-02       Impact factor: 3.181

3.  No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort.

Authors:  Roberto Del Bo; Stefania Corti; Domenico Santoro; Isabella Ghione; Chiara Fenoglio; Serena Ghezzi; Michela Ranieri; Daniela Galimberti; Michelangelo Mancuso; Gabriele Siciliano; Chiara Briani; Luigi Murri; Elio Scarpini; Jennifer C Schymick; Bryan J Traynor; Nereo Bresolin; Giacomo P Comi
Journal:  Neurobiol Aging       Date:  2009-07-25       Impact factor: 4.673

4.  Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

Authors:  Jun Wang; Philip Van Damme; Carlos Cruchaga; Michael A Gitcho; Jose Manuel Vidal; Manuel Seijo-Martínez; Lei Wang; Jane Y Wu; Wim Robberecht; Alison Goate
Journal:  J Neurochem       Date:  2009-12-17       Impact factor: 5.372

5.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

Review 6.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

7.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

8.  C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease.

Authors:  Matthew Harms; Bruno A Benitez; Nigel Cairns; Breanna Cooper; Paul Cooper; Kevin Mayo; David Carrell; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Richard Mayeux; Sumitra Chakraverty; Alison M Goate; Carlos Cruchaga
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

Review 9.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

10.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.

Authors:  NiCole Finch; Matt Baker; Richard Crook; Katie Swanson; Karen Kuntz; Rebecca Surtees; Gina Bisceglio; Anne Rovelet-Lecrux; Bradley Boeve; Ronald C Petersen; Dennis W Dickson; Steven G Younkin; Vincent Deramecourt; Julia Crook; Neill R Graff-Radford; Rosa Rademakers
Journal:  Brain       Date:  2009-01-21       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.